Trial Profile
Hemodynamic Response of Rifaximin and Non-selective β-blocker Combination Therapy Versus Non-selective β-blocker Monotherapy in Cirrhotic Patients With Esophageal Varices
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 06 Jun 2017
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Portal hypertension
- Focus Therapeutic Use
- Acronyms RECOVER
- 06 Jul 2015 New trial record